Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Daily RAD001 Administered Orally in Combination With Mitomycin C, Administered Every Three Weeks to Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction

NCT01042782 is registered in ClinicalTrials.gov with Krankenhaus Nordwest as lead sponsor.

NCT NCT01042782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01042782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Daily RAD001 Administered Orally in Combination With Mitomycin C, Administered Every Three Weeks to Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction
Lead sponsor
Krankenhaus Nordwest
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
August 31, 2012
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer of the esophagogastric junction, advanced gastric cancer